Shuiying Hu

4.8k total citations
94 papers, 3.5k citations indexed

About

Shuiying Hu is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Shuiying Hu has authored 94 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 32 papers in Molecular Biology and 23 papers in Hematology. Recurrent topics in Shuiying Hu's work include Drug Transport and Resistance Mechanisms (44 papers), Pharmacogenetics and Drug Metabolism (17 papers) and Cancer Treatment and Pharmacology (16 papers). Shuiying Hu is often cited by papers focused on Drug Transport and Resistance Mechanisms (44 papers), Pharmacogenetics and Drug Metabolism (17 papers) and Cancer Treatment and Pharmacology (16 papers). Shuiying Hu collaborates with scholars based in United States, Netherlands and Italy. Shuiying Hu's co-authors include Alex Sparreboom, Sharyn D. Baker, Mingzhao Xing, Shelley Orwick, Alice A. Gibson, Dingxie Liu, Peng Hou, Vasily Vasko, Lie Li and Ryan M. Franke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Nature Communications.

In The Last Decade

Shuiying Hu

89 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuiying Hu United States 32 1.7k 1.3k 696 505 406 94 3.5k
Kenichi Furihata Japan 30 662 0.4× 1.1k 0.9× 281 0.4× 1.3k 2.5× 250 0.6× 118 3.9k
Cody J. Peer United States 33 1.5k 0.9× 1.8k 1.4× 187 0.3× 172 0.3× 97 0.2× 156 4.0k
Douglas K. Price United States 34 1.1k 0.7× 1.6k 1.2× 323 0.5× 156 0.3× 187 0.5× 114 3.3k
Sumio Kawata Japan 45 984 0.6× 1.8k 1.4× 673 1.0× 119 0.2× 98 0.2× 181 6.1k
Helen L. Reeves United Kingdom 36 1.3k 0.8× 2.2k 1.7× 895 1.3× 168 0.3× 72 0.2× 95 8.3k
Tristan M. Sissung United States 30 1.4k 0.8× 1.2k 1.0× 155 0.2× 116 0.2× 296 0.7× 94 2.9k
Horst Schran United States 28 1.1k 0.7× 626 0.5× 234 0.3× 898 1.8× 231 0.6× 70 3.0k
Piter J. Bosma Netherlands 34 2.5k 1.5× 2.5k 1.9× 201 0.3× 285 0.6× 2.6k 6.4× 91 6.4k
Andrew G. Hall United Kingdom 36 756 0.4× 2.2k 1.8× 77 0.1× 863 1.7× 401 1.0× 118 4.0k
Jacques Jolivet Canada 29 1.0k 0.6× 1.7k 1.3× 71 0.1× 798 1.6× 278 0.7× 91 3.9k

Countries citing papers authored by Shuiying Hu

Since Specialization
Citations

This map shows the geographic impact of Shuiying Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuiying Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuiying Hu more than expected).

Fields of papers citing papers by Shuiying Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuiying Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuiying Hu. The network helps show where Shuiying Hu may publish in the future.

Co-authorship network of co-authors of Shuiying Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Shuiying Hu. A scholar is included among the top collaborators of Shuiying Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuiying Hu. Shuiying Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Yue, Eman Ahmed, Kevin M. Huang, et al.. (2025). Strain-dependent neuronal disposition and toxicity of paclitaxel in mice. 1. 100005–100005. 1 indexed citations
2.
Ahmed, Eman, et al.. (2025). Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice. Molecules. 30(7). 1440–1440. 1 indexed citations
3.
Huang, Kevin M., Peter de Bruijn, Mahesh R. Nepal, et al.. (2024). Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen. Cancer Research Communications. 4(9). 2489–2497. 2 indexed citations
4.
Talebi, Zahra, Yan Jin, Alice A. Gibson, et al.. (2024). Darolutamide does not interfere with OATP‐mediated uptake of docetaxel. International Journal of Cancer. 155(2). 314–323. 3 indexed citations
5.
Nepal, Mahesh R., Yang Li, Zahra Talebi, et al.. (2022). Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity. Cancer Research Communications. 2(11). 1334–1343. 7 indexed citations
6.
Jin, Yan, Zahra Talebi, Shuiying Hu, et al.. (2022). Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B. Molecules. 27(20). 6815–6815. 5 indexed citations
7.
Li, Yang, Yan Jin, Keith T. Schmidt, et al.. (2022). A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities. Pharmaceutics. 14(9). 1933–1933. 5 indexed citations
8.
Chen, Mingqing, Alice A. Gibson, Shichen Shen, et al.. (2021). Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation. Clinical Cancer Research. 27(15). 4301–4310. 27 indexed citations
9.
Huang, Kevin M., et al.. (2020). Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. Reviews of physiology, biochemistry and pharmacology. 183. 177–215. 7 indexed citations
10.
Dwivedi, Pankaj, Rong Fan, Anil Kumar Dwivedi, et al.. (2019). Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. Materials Science and Engineering C. 102. 113–123. 26 indexed citations
11.
Drenberg, Christina D., Alice A. Gibson, Stanley Pounds, et al.. (2017). OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Research. 77(8). 2102–2111. 46 indexed citations
12.
Zimmerman, Eric I., Alice A. Gibson, Shuiying Hu, et al.. (2016). Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. Cancer Research. 76(1). 117–126. 38 indexed citations
13.
Nieuweboer, Annemieke J.M., Shuiying Hu, Chunshan Gui, et al.. (2014). Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel. Cancer Research. 74(11). 3137–3145. 47 indexed citations
14.
Zimmerman, Eric I., Shuiying Hu, Alice A. Gibson, et al.. (2013). Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide. Clinical Cancer Research. 19(6). 1458–1466. 131 indexed citations
15.
Nies, Anne T., Elke Schaeffeler, Heiko van der Kuip, et al.. (2013). Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). Clinical Cancer Research. 20(4). 985–994. 52 indexed citations
16.
Graan, Anne‐Joy M. de, Cynthia S. Lancaster, Amanda Obaidat, et al.. (2012). Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research. 18(16). 4433–4440. 76 indexed citations
17.
Hu, Chaoxin, Cynthia S. Lancaster, Zhili Zuo, et al.. (2012). Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics. 11(4). 921–929. 54 indexed citations
18.
Hu, Shuiying, Zhaoyuan Chen, Ryan M. Franke, et al.. (2009). Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters. Clinical Cancer Research. 15(19). 6062–6069. 129 indexed citations
19.
Hu, Shuiying, Hongmei Niu, Shelley Orwick, et al.. (2008). Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular Cancer Therapeutics. 7(5). 1110–1120. 31 indexed citations
20.
Lü, Bin, Liying Wang, Christian Stehlik, et al.. (2006). Phosphatidylinositol 3-Kinase/Akt Positively Regulates Fas (CD95)-Mediated Apoptosis in Epidermal Cl41 Cells. The Journal of Immunology. 176(11). 6785–6793. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenichi Furihata Breakdown of academic impact, for papers by Cody J. Peer Breakdown of academic impact, for papers by Douglas K. Price Breakdown of academic impact, for papers by Sumio Kawata Breakdown of academic impact, for papers by Helen L. Reeves Breakdown of academic impact, for papers by Tristan M. Sissung Breakdown of academic impact, for papers by Horst Schran Breakdown of academic impact, for papers by Piter J. Bosma Breakdown of academic impact, for papers by Andrew G. Hall Breakdown of academic impact, for papers by Jacques Jolivet
Rankless by CCL
2026